title: ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
abstract: OBJECTIVE
  To evaluate (18)F-fluorodeoxyglucose (FDG) uptake to predict the malignant nature and analyze the correlation between FDG uptake and expression of glucose transporter 1 (Glut-1) and hexokinase II (HK-II) in thymic epithelial tumors.
  
  
  METHODS
  Eleven patients with a thymic epithelial tumor who underwent FDG PET/CT before therapy were reviewed. The thymic tumors were classified by the WHO histological classification and Masaoka clinical staging. Comparison of maximum standardized uptake value (SUV(max)) of the lesion was made between the low-risk (Type A, AB and B1) and high-risk {Type B2, B3 and C (thymic cancer)} groups and among clinical stages. Expression of Glut-1 and HK-II was analyzed immunohistochemically.
  
  
  RESULTS
  All 11 tumors showed FDG uptake visually. SUV(max) was significantly higher in the high-risk group (n=5, 5.24 ± 2.44) than the low-risk group (n=6, 3.05 ± 0.55) (P=0.008). Staining scores of both Glut-1 and HK-II were significantly higher in the high-risk group than in the low-risk group (Glut1: P=0.034 and HK-II: P=0.036). There were no significant differences in SUV(max) (P=0.11), Glut-1 (P=0.35) and HK-II scores (P=0.29) among clinical stages. SUV(max) was significantly correlated to each of the staining scores of Glut-1 (ρ=0.68, P=0.031) and HK-II (ρ=0.72, P=0.024).
  
  
  CONCLUSIONS
  These preliminary results support the previously published view that SUV(max) may be useful to predict the malignant nature of thymic epitherial tumors and suggest that the degree of FDG uptake in the thymic epitherial tumors is closely related to the amount of Glut-1 and HK-II in the tumor.
authors.affiliation: Department of Radiology, Nanpuh Hospital, 14-3 Nagata, Kagoshima 892-8512, Japan. toyo.nakajo@dolphin.ocn.ne.jp
authors.forename: Masatoyo
authors.initials: M
authors.lastname: Nakajo
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Kajiya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tani
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoneda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shirahama
authors.forename: Michiyo
authors.initials: M
authors.lastname: Higashi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nakajo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D006593:Hexokinase / Q000378:metabolism*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D060787:Neoplasm Grading; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012307:Risk Factors; D013953:Thymus Neoplasms / Q000175:diagnosis* / Q000378:metabolism*
chemical_list: D051272:Glucose Transporter Type 1; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C472074:HK1 protein, human; D006593:Hexokinase